Skip to main content

STRO

Stock
Health Care
Biotechnology

Performance overview

STRO Price
Price Chart

Forward-looking statistics

Beta
1.78
Risk
81.09%

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Company Profile

Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. It is mainly engaged in the development of biopharmaceutical products. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and non-Hodgkin lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers.

Company info

SectorHealth Care
IndustryBiotechnology
Employees292
Market cap$303.5M

Fundamentals

Enterprise value-$167.3M
Revenue$66.4M
Revenue per employee—
Profit margin0.00%
Debt to equity-0.83

Security info

ExchangeNASDAQ
Type of shareCommon Stock
Earnings per share (EPS)-$2.92
Dividend per share—
Revenue per share$0.81
Avg trading volume (30 day)$886K
Avg trading volume (10 day)$1M
Put-call ratio—

Macro factor sensitivity

Growth-0.5
Credit+6.2
Liquidity-0.9
Inflation-3.6
Commodities-2.6
Interest Rates-1.8

Valuation

Dividend yield0.00%
PEG Ratio-0.26
Price to sales0.97
P/E Ratio-0.26
Enterprise Value to Revenue-2.52
Price to book-2.41

Upcoming events

Next earnings dayMay 9, 2025
Next dividend day—
Ex. dividend day—

News

Sutro Biopharma, Inc. (STRO) Reports Q1 Loss, Tops Revenue Estimates

Sutro Biopharma, Inc. (STRO) came out with a quarterly loss of $0.91 per share versus the Zacks Consensus Estimate of a loss of $0.63. This compares to loss of $0.95 per share a year ago.

Zacks Investment Research (May 8, 2025)
Penny Stock Sutro Biopharma Cuts Costs, Refocuses Pipeline

On Thursday, Sutro Biopharma, Inc. STRO prioritized its antibody-drug conjugates (ADC) pipeline, including three wholly-owned preclinical programs in its next-generation ADC pipeline.

Benzinga (March 14, 2025)

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free